PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
D/E ratio under 0.3 - Rock-solid balance sheet territory. Warren Buffett would approve, but check if ROE is being sacrificed. Consider examining Interest Coverage to confirm debt serviceability.
3.31
Net debt 3-4x EBITDA - Concerning leverage levels. Howard Marks would demand exceptional business stability. Essential to verify Debt-to-Equity and Interest Coverage.
No Data
No Data available this quarter, please select a different quarter.
1.37
Current ratio 1.2-1.5 - Adequate liquidity that Peter Lynch might accept. Cross-check Interest Coverage to ensure overall financial health.
No Data
No Data available this quarter, please select a different quarter.